Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cogstate Ltd ( (AU:CGS) ) has shared an announcement.
Cogstate Limited has announced a change in the interest of its director, Bradley O’Connor, as per the latest notice. The update reveals that 500,000 employee options have lapsed due to unmet performance conditions, impacting the director’s holdings. This change reflects the company’s ongoing adjustments in its executive compensation and performance evaluation strategies, which may influence stakeholder perceptions and market positioning.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Limited operates in the healthcare industry, specializing in cognitive science and technology. The company provides digital brain health assessments and services, primarily focusing on clinical trials and research in neurology and psychiatry.
Average Trading Volume: 86,270
Technical Sentiment Signal: Buy
Current Market Cap: A$289.1M
Find detailed analytics on CGS stock on TipRanks’ Stock Analysis page.